

doi: 10.13241/j.cnki.pmb.2018.15.037

慢性阻塞性肺疾病患者血清 NE、 α 1-AT、CRP、PCT 的表达及与肺功能的关系研究

杨继雷¹ 姚秀叶² 袁晓飞³ 谷伟¹ 王存美⁴ 黄攀登¹ 董立平¹ 刘晓兰⁵

(1 河北北方学院附属第一医院老年科 河北 张家口 075000; 2 河北北方学院附属第一医院皮肤科 河北 张家口 075000;

3 河北北方学院附属第一医院血液科 河北 张家口 075000; 4 张家口市环境监测站 河北 张家口 075000;

5 张家口市第一医院病案科 河北 张家口 075041)

摘要 目的: 探讨慢性阻塞性肺疾病 (COPD) 患者血清中性粒细胞弹性蛋白酶 (NE)、 α 1- 抗胰蛋白酶 (α 1-AT)、C- 反应蛋白 (CRP)、降钙素原 (PCT) 的表达水平及其与肺功能的相关性。**方法:** 选取 2013 年 3 月 -2015 年 6 月河北北方学院附属第一医院呼吸内科收治的 COPD 患者 87 例作为研究对象, 其中急性加重期(急性组)患者 49 例, 稳定期(稳定组)患者 38 例, 另选取同时期在本院进行健康体检的志愿者 30 例为对照组, 检测并对比急性组、稳定组和对照组受试者的血清 NE、 α 1-AT、CRP、PCT 水平及肺功能指标, 并分析 COPD 患者 NE、 α 1-AT、CRP、PCT 水平与肺功能的相关性。**结果:** 与对照组对比, 急性组与稳定组患者的 NE、CRP、PCT 水平均明显升高, α 1-AT 水平明显降低($P<0.05$), 且急性组患者的 NE、CRP、PCT 水平高于稳定组, α 1-AT 水平低于稳定组($P<0.05$); 急性组与稳定组患者的第 1 秒用力呼气容积占预计值的百分比(FEV1%)、第 1 秒用力呼气容积 / 用力肺活量 (FEV1/FVC) 均低于对照组, 且急性组 FEV1%、FEV1/FVC 低于稳定组($P<0.05$); 经 Spearman 相关性分析显示, NE、CRP、PCT 与 FEV1% 及 FEV1/FVC 均呈负相关, α 1-AT 与 FEV1% 及 FEV1/FVC 呈正相关($P<0.05$)。**结论:** COPD 患者血清 NE、CRP、PCT 表达水平均明显升高, α 1-AT 表达水平明显降低, 且 NE、 α 1-AT、CRP、PCT 均与肺功能存在一定相关性, 加强对此类指标的监测有助于对 COPD 患者病情判断及治疗指导。

关键词: 慢性阻塞性肺疾病; 中性粒细胞弹性蛋白酶; α 1- 抗胰蛋白酶; C- 反应蛋白; 降钙素原; 肺功能

中图分类号:R563 文献标识码:**A** 文章编号:1673-6273(2018)15-2966-04

Chronic Obstructive Pulmonary Disease: Expression of Serum Protease, Antiprotease, C-reactive Protein and Procalcitonin and Their Relationship with Pulmonary Function

YANG Ji-lei¹, YAO Xiu-ye², YUAN Xiao-fei³, GU Wei¹, WANG Cun-mei⁴, HUANG Pan-deng¹, DONG Li-ping¹, LIU Xiao-lan⁵

(1 Department of Geriatric, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China; 2 Department of Dermatology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China; 3 Department of Hematology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China; 4 Zhangjiakou Environmental Monitoring Station, Zhangjiakou, Hebei, 075000, China; 5 Department of Medical Records, The First Hospital of Zhangjiakou, Zhangjiakou, Hebei, 075041, China)

ABSTRACT Objective: To investigate the expression of neutral granulocyte elastase (NE), α 1- antitrypsin (α 1-AT), C-reactive protein (CRP) and procalcitonin (PCT) in patients with chronic obstructive pulmonary disease (COPD) and its correlation with pulmonary function. **Methods:** A total of 87 COPD patients, who were treated in First Affiliated Hospital of Hebei North University from March 2013 to June 2015, were chosen as subjects, among them, 49 cases were acute exacerbation (acute group), 38 cases were stable phase (stable group); another 30 volunteers, who underwent physical examination during the same period, were chosen as control group. The serum levels of NE, α 1-AT, CRP, PCT and pulmonary function in the acute group, stable group and control group were detected and compared, the correlation of NE, α 1-AT, CRP and PCT levels with pulmonary function in COPD patients was analyzed. **Results:** Compared with the control group, the levels of NE, CRP and PCT in the acute group and the stable group were significantly increased, and the level of α 1-AT was significantly lower ($P<0.05$); the levels of NE, CRP and PCT in the acute group were higher than those in the stable group, and the level of α 1-AT was lower than that in the stable group ($P<0.05$). Percentage of forced expiratory volume at first second to predicted value (FEV1%) and forced expiratory volume at first second to forced vital capacity (FEV1/FVC) in the acute and the stable group were lower than those in the control group, FEV1%, FEV1/FVC in the acute group was lower than that in the stable group ($P<0.05$). Spearman correlation analysis showed that NE, CRP and PCT were negatively correlated with FEV1% and FEV1/FVC, and α 1-AT was positively correlated with FEV1% and FEV1/FVC ($P<0.05$). **Conclusion:** The levels of serum NE, CRP and PCT in the patients with

作者简介:杨继雷(1980-),男,硕士,主治医师,从事呼吸病学方面的研究,E-mail:rweogn@163.com

(收稿日期:2017-10-23 接受日期:2017-11-18)

COPD are significantly increased, the expression level of $\alpha 1$ -AT is obviously decreased, and NE, $\alpha 1$ -AT, CRP and PCT are related to pulmonary function. To strengthen the monitoring of such indicators is helpful for the diagnosis and treatment of COPD patients.

Key words: Chronic obstructive pulmonary disease; Neutral granulocyte elastase; $\alpha 1$ -antitrypsin; C-reactive protein; Procalcitonin; Pulmonary function

Chinese Library Classification(CLC): R563 Document code: A

Article ID: 1673-6273(2018)15-2966-04

前言

慢性阻塞性肺疾病(Chronic obstructive pulmonary disease, COPD)是临床常见的呼吸系统疾病,具有较高的发病率及病死率^[1,2]。COPD 患者在急性发作期后,部分临床症状可出现一定的缓解,但是其肺功能仍呈现为进行性恶化,并且容易反复发作,严重影响了患者的生活质量^[3-5]。目前临幊上对于 COPD 的发病机制尚未明确,有研究提出蛋白酶 - 抗蛋白酶系统失衡是引发 COPD 的重要因素,其中较为重要的是 $\alpha 1$ - 抗胰蛋白酶($\alpha 1$ - antitrypsin, $\alpha 1$ -AT)与中性粒细胞弹性蛋白酶(Neutrophil elastase, NE)的失衡^[6-8]。另有研究表明^[9-11],COPD 的本质是肺实质、气道和肺血管的慢性炎症反应,炎症反应所释放的炎症介质使中性粒细胞的炎症反应加剧以及肺结构破坏,进而引发气流受限。降钙素原(Procalcitonin, PCT)、C 反应蛋白(C reactive protein, CRP)作为机体重要的炎性标志物,均参与了 COPD 患者急性加重期的炎症反应^[12-14]。本研究对 COPD 患者血清 NE、 $\alpha 1$ -AT、CRP、PCT 表达水平及其与肺功能的相关性进行探讨,旨在对 COPD 患者病情判断及治疗指导提供方向,结果如下。

1 资料与方法

1.1 一般资料

选取 2013 年 3 月 -2015 年 6 月河北北方学院附属第一医院呼吸内科收治的 COPD 患者 87 例为研究对象。纳入标准:(1)所有入选患者均符合中华医学会呼吸病学分会慢性阻塞性肺疾病学组《慢性阻塞性肺疾病诊治指南》中的诊断标准^[15];(2)患者对本研究知情同意并签署知情同意书。排除标准:(1)伴有急性或慢性感染的患者;(2)伴有其他慢性肺部疾病的患者;(3)伴有肝肾功能不全的患者;(4)伴有恶性肿瘤的患者;(5)生命体征不稳定的患者。87 例 COPD 患者中急性加重期(急性组)患者 49 例,稳定期(稳定组)患者 38 例。急性组患者中男 30 例,女 19 例,年龄 45-78 岁,平均年龄(62.31 ± 5.93)岁;稳定组患者中男 21 例,女 17 例,年龄 43-77 岁,平均年龄(61.42 ± 5.46)岁。另选取同时期在本院进行健康体检的志愿者

30 例为对照组,其中男 18 例,女 12 例,年龄 45-79 岁,平均年龄 (63.94 ± 5.68) 岁。三组的临床资料对比无显著差异($P > 0.05$)。本研究通过医院伦理委员会批准。

1.2 方法

抽取所有受试者的空腹静脉血 5 mL, 应用离心机以 2000 r/min 的转速离心 20 min, 离心半径为 10 cm, 抽取上清液, 置于 -70°C 温度下保存, 其中 NE 与 $\alpha 1$ -AT 水平采用酶联免疫吸附法进行检测, CRP 水平采用免疫比浊法进行检测, PCT 水平采用免疫荧光双抗体夹心法进行检测, 所有操作均严格按照试剂盒说明进行, 试剂盒均由石家庄麦迪克试剂公司提供。肺功能指标采用肺功能仪(德国耶格公司生产, 型号:HI-101 Master Screen)进行检测, 检测指标包括用力肺活量(Forced vital capacity, FVC)、第 1 秒用力呼气容积(Forced expiratory volume in one second, FEV1), 并计算第 1 秒用力呼气容积 / 用力肺活量(FEV1/FVC)、第 1 秒用力呼气容积占预计值的百分比(FEV1%)。

1.3 观察指标

检测并对比 COPD 急性组、稳定组和对照组的血清 NE、 $\alpha 1$ -AT、CRP、PCT 水平及肺功能指标,并分析 COPD 患者血清 NE、 $\alpha 1$ -AT、CRP、PCT 水平与肺功能的相关性。

1.4 统计学方法

采用 SPSS19.0 统计学软件对数据进行统计学处理, 计量资料均以($\bar{x} \pm s$)的形式表示, 组间对比经 t 检验分析, 多组间对比经方差分析, 计数资料以(%)的形式表示, 经 χ^2 检验分析, NE、 $\alpha 1$ -AT、CRP、PCT 水平与肺功能的相关性采用 Spearman 相关性分析, 以 $P < 0.05$ 为差异有统计学意义。

2 结果

2.1 三组受试者血清 NE、 $\alpha 1$ -AT、CRP、PCT 水平对比

与对照组对比,COPD 急性组与稳定组患者的 NE、CRP、PCT 水平均明显升高, $\alpha 1$ -AT 水平明显降低($P < 0.05$),且急性组患者的 NE、CRP、PCT 水平高于稳定组, $\alpha 1$ -AT 水平低于稳定组($P < 0.05$)。见表 1。

表 1 三组受试者血清 NE、 $\alpha 1$ -AT、CRP、PCT 水平对比($\bar{x} \pm s$)

Table 1 Comparison of serum NE, $\alpha 1$ -AT, CRP and PCT levels among three groups($\bar{x} \pm s$)

Groups	n	NE($\mu\text{g/L}$)	$\alpha 1$ -AT(mg/L)	CRP(mg/L)	PCT(ng/mL)
Acute group	49	$100.93 \pm 20.72^{**}$	$8687.74 \pm 2156.73^{**}$	$33.49 \pm 4.27^{**}$	$5.19 \pm 1.32^{**}$
Stable group	38	$78.65 \pm 12.57^*$	$12443.69 \pm 4512.67^*$	$17.29 \pm 2.43^*$	$1.63 \pm 0.45^*$
Control group	30	58.81 ± 10.16	19733.57 ± 5142.38	6.02 ± 1.37	0.57 ± 0.14
F	-	9.156	12.187	10.174	7.312
P	-	0.036	0.012	0.021	0.039

Note: compared with control group, * $P < 0.05$; compared with stable group, ** $P < 0.05$.

2.2 三组受试者肺功能指标对比

COPD 急性组与稳定组患者的 FEV1%、FEV1/FVC 均低于

对照组，且 COPD 急性组 FEV1%、FEV1/FVC 低于稳定组 ($P<0.05$)。见表 2。

表 2 三组受试者肺功能指标对比($\bar{x}\pm s$)

Table 2 Comparison of pulmonary function indexes among three groups ($\bar{x}\pm s$)

Groups	n	FEV1%	FEV1/FVC(%)
Acute group	49	48.09± 10.12*#	51.38± 7.14*#
Stable group	38	65.67± 12.57*	65.17± 8.54*
Control group	30	97.28± 9.73	89.64± 12.73
F	-	10.539	13.827
P	-	0.018	0.006

Note: compared with control group, * $P<0.05$; compared with stable group, # $P<0.05$.

2.3 COPD 患者血清 NE、 $\alpha 1$ -AT、CRP、PCT 水平与肺功能的相关性分析

经 Spearman 相关性分析显示, COPD 患者血清 NE、CRP、

PCT 水平与 FEV1% 及 FEV1/FVC 均呈负相关, $\alpha 1$ -AT 水平与 FEV1% 及 FEV1/FVC 呈正相关 ($P<0.05$), 见表 3。

表 3 COPD 患者血清 NE、 $\alpha 1$ -AT、CRP、PCT 水平与肺功能的相关性分析

Table 3 Correlation analysis of serum NE, $\alpha 1$ -AT, CRP, PCT levels and pulmonary function in patients with COPD

Indexes	FEV1%		FEV1/FVC	
	r	P	r	P
NE	-0.714	0.014	-0.638	0.026
$\alpha 1$ -AT	0.512	0.003	0.631	0.005
CRP	-0.476	0.032	-0.571	0.028
PCT	-0.331	0.039	-0.375	0.035

3 讨论

COPD 是以气流受限为特征的肺气肿或慢性支气管炎, 慢性炎症的修复与损伤在 COPD 的发生与发展中发挥着重要的作用^[16,17]。NE 在炎症反应过程中具有双重作用, 一方面可影响中性粒细胞的迁移、黏附以及降解多种前炎症细胞因子, 对炎症反应的发生具有一定程度的抑制作用;另一方面可促进上皮细胞对多种促炎细胞因子的释放, 加剧炎症反应强度^[18,19]。 $\alpha 1$ -AT 是由肝细胞产生的抗蛋白酶, 对 NE 具有较强的抑制作用, 其作用主要是对蛋白酶的活性进行抑制, 进而避免肺部组织受到蛋白溶酶的损坏^[20]。本研究结果显示, COPD 患者的 NE 水平高于对照组, 且 COPD 急性组 NE 水平高于稳定组, 对照组与 COPD 稳定组 $\alpha 1$ -AT 的水平高于 COPD 急性组, 提示在 COPD 急加重期 NE 呈现为较高的表达水平, 而 $\alpha 1$ -AT 表达水平较低, 分析其原因主要是因为 COPD 患者在急性加重期炎症反应加剧, 受到炎症因子的作用, 导致中性粒细胞大量释放 NE, 进而 NE 水平急剧上升, COPD 稳定期患者部分 NE 被抗蛋白酶拮抗, 其水平低于急性加重期, 但仍高于正常人群。在 COPD 急加重期 $\alpha 1$ -AT 水平降低, 导致蛋白酶-抗蛋白酶系统失衡, 下呼吸道 NE 水平相对增多, 使得肺组织不断受到损坏, 进而引发肺气肿等临床症状^[21,22]。CRP 是机体受到组织损伤或炎症反应刺激所产生的急性时相反应蛋白, 其表达水平不受免疫抑制剂、激素等药物的影响, 是反映机体炎症反应的敏感指标之一^[23-25]。PCT 是降钙素前体, 在预测与评估严重炎症性疾病中具有重要作用^[26,27]。本研究结果显示, CRP 与 PCT 在

COPD 急性组中的表达水平明显高于稳定组与对照组, 且在稳定组中的表达水平明显高于对照组, 说明 CRP 与 PCT 在 COPD 患者中的表达水平高于正常人群, 且在急性加重期其水平出现异常升高。分析其原因主要是因为 COPD 患者在急性加重期炎症反应及肺组织损伤加剧, 进而导致血清中 CRP 及 PCT 的水平异常升高。

肺功能检查是评估气流受限较好的客观指标, 对诊断与评估 COPD 严重程度、病情进展、治疗及预后均具有重要的意义^[28-30]。本研究结果显示, COPD 急性组与稳定组患者的 FEV1%、FEV1/FVC 均低于对照组, 且 COPD 急性组 FEV1%、FEV1/FVC 低于稳定组, 说明 COPD 患者的肺功能在急性加重期急剧下降, 进而使患者的病情加重, 分析其原因为 COPD 患者在急性加重期气道受限程度较稳定期及正常人群更严重, 使得机体缺氧、肺泡通气不足、CO₂ 潘留越严重, 致使患者病情加重, 肺功能降低。在 COPD 患者血清 NE、 $\alpha 1$ -AT、CRP、PCT 水平与肺功能的相关性分析中显示, NE、CRP、PCT 水平与 FEV1% 及 FEV1/FVC 均呈负相关, $\alpha 1$ -AT 与 FEV1% 及 FEV1/FVC 呈正相关, 说明 NE、CRP、PCT 在 COPD 在急性发病过程中发挥着重要作用, NE、CRP、PCT 水平的升高可严重损坏机体肺功能, $\alpha 1$ -AT 则对肺组织具有保护作用。

综上所述, COPD 患者血清中 NE、CRP、PCT 表达水平均明显升高, $\alpha 1$ -AT 表达水平明显降低, 且与肺功能也存在一定相关性, 临幊上可根据此类指标的水平变化以判断 COPD 患者病情, 同时对治疗也可以提供依据。

参考文献(References)

- [1] Alibašić E, Skopljak A, Čengić A, et al. Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life[J]. *Med Glas (Zenica)*, 2017, 14(2): 182-188
- [2] Čelutkienė J, Balčiūnas M, Kablučko D, et al. Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease[J]. *Card Fail Rev*, 2017, 3(1): 56-61
- [3] Hoaas H, Morseth B, Holland AE, et al. Are Physical activity and Benefits Maintained After Long-Term Telerehabilitation in COPD? [J]. *Int J Telerehabil*, 2016, 8(2): 39-48
- [4] Tsai LLY, McNamara RJ, Dennis SM, et al. Satisfaction and Experience With a Supervised Home-Based Real-Time Videoconferencing Telerehabilitation Exercise Program in People with Chronic Obstructive Pulmonary Disease (COPD) [J]. *Int J Telerehabil*, 2016, 8(2): 27-38
- [5] Goldman RE, Mennillo L, Stebbins P, et al. How do patients conceptualize chronic obstructive pulmonary disease? [J]. *Chron Respir Dis*, 2017, 14(3): 245-255
- [6] Henneuse A, Suchon P, Chambost H, et al. α 1-antitrypsin Pittsburgh and plasmin-mediated proteolysis [J]. *J Thromb Haemost*, 2016, 14(10): 2023-2026
- [7] Huang X, Zheng Y, Zhang F, et al. Molecular Mechanism of Z α 1-Antitrypsin Deficiency[J]. *J Biol Chem*, 2016, 291(30): 15674-15686
- [8] Loke I, Østergaard O, Heegaard NHH, et al. Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil ElastaseModulates Its Immune Functions [J]. *Mol Cell Proteomics*, 2017, 16(8): 1507-1527
- [9] Mohammed J, Da Silva H, Van Oosterwijck J, et al. Effect of respiratory rehabilitation techniques on the autonomic function in patients with chronic obstructive pulmonary disease: A systematic review[J]. *Chron Respir Dis*, 2017, 14(3): 217-230
- [10] Verduri A, Luppi F, D'Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease Withprocalcitonin:a randomized noninferiority trial [J]. *PLoS One*, 2015, 10(3): e011824
- [11] Usuki T, Sugimura T, Komatsu A, et al. Biomimetic Chichibabin pyridine synthesis of the COPD biomarkers and elastin cross-linkers isodesmosine and desmosine[J]. *Org Lett*, 2014, 16(6): 1672-1675
- [12] Emami Ardestani M, Zaerin O. Role of Serum Interleukin 6, Albumin and C-Reactive Protein in COPD Patients [J]. *Tanaffos*, 2015, 14(2): 134-140
- [13] Picart J, Moiton MP, Gauzère B A, et al. Introduction of a PCT-based algorithm to guide antibiotic prescription in COPD exacerbation[J]. *Med Mal Infect*, 2016, 46(8): 429-435
- [14] Gilbert DN. Role of Procalcitonin in the Management of Infected Patients in the Intensive Care Unit [J]. *Infect Dis Clin North Am*, 2017, 31(3): 435-453
- [15] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. *中华结核和呼吸杂志*, 2013, 36(4): 255-264
Chronic obstructive pulmonary disease study group of Chinese Medical Association Respiratory Diseases Branch. Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease(Revised Edition, 2013)[J]. *Chinese Journal of Tuberculosis and Respiratory Diseases*, 2013, 36(4): 255-264
- [16] Rahimi-Ead MH, Sadighi T, Rabieepour M, et al. Prevalence of anemia and its impact on mortality in patients with acute exacerbation of chronic obstructive pulmonary disease in a developing country setting[J]. *Pneumologia*, 2015, 64(3): 27-30
- [17] Machado Rodrigues F, Demeyer H, Hornikx M, et al. Validity and reliability of strain gauge measurement of volitional quadriceps force in patients with COPD[J]. *Chron Respir Dis*, 2017, 14(3): 289-297
- [18] 马涛, 黄璐, 赵阳, 等. 针灸对肝郁化火型失眠患者 NE 及 PKC, BDNF 表达水平的影响[J]. *现代生物医学进展*, 2016, 16(21): 4071-4074
Ma Tao, Huang Lu, Zhao Yang, et al. Effects of Acupuncture on NE Content and PKC, BDNF Gene Expression in Patients with Insomnia of Type of Stagnation of Liver Fire [J]. *Progress in Modern Biomedicine*, 2016, 16(21): 4071-4074
- [19] Vergelli C, Schepetkin IA, Crocetti L, et al. Isoxazol-5 (2H)-one: a new scaffold for potent human neutrophil elastase(HNE) inhibitors[J]. *J Enzyme Inhib Med Chem*, 2017, 32(1): 821-831
- [20] Joly P, Restier L, Boucheareilh M, et al. DEFI-ALPHA cohort and POLYGEN DEFI-ALPHA clinical research hospital programme. A study about clinical, biological and genetics factors associated with the occurrence and the evolution of hepatic complications in children with alpha-1 antitrypsin deficiency [J]. *Rev Mal Respir*, 2015, 32(7): 759-767
- [21] O'Meara A, Kapel N, Xhaard A, et al. Fecal calprotectin and α 1-antitrypsin dynamics in gastrointestinal GvHD [J]. *Bone Marrow Transplant*, 2015, 50(8): 1105-1109
- [22] Tamura K, Takashima H, Fumoto K, et al. Possible Role of α 1-Antitrypsin in Endometriosis-Like Grafts From a Mouse Model of Endometriosis[J]. *Reprod Sci*, 2015, 22(9): 1088-1097
- [23] Zhang H, Wang X, Zhang Q, et al. Comparison of procalcitonin and high-sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients[J]. *BMC Geriatr*, 2017, 17(1): 173
- [24] 赵明丽, 王玉忠, 张露露, 等. COPD 合并肺心病患者血清 hs-CRP、BNP 的含量及临床意义 [J]. *中国实验诊断学*, 2016, 20(10): 1670-1672
Zhao Ming-li, Wang Yu-zhong, Zhang Lu-lu, et al. Correlational studies of serum hs-CRP, BNP level and their clinical significance and patients with COPD complicated with pulmonary heart disease [J]. *Chinese Journal of Laboratory Diagnosis*, 2016, 20(10): 1670-1672
- [25] Yang JS, Gerber JN, You HJ. Association between fasting insulin and high-sensitivity C reactive protein in Korean adults [J]. *BMJ Open Sport Exerc Med*, 2017, 3(1): e000236
- [26] Möckel M, Searle J, Maisel A. The role of procalcitonin in acute heart failure patients[J]. *ESC Heart Fail*, 2017, 4(3): 203-208
- [27] He C, Wang B, Wang YF, et al. Can procalcitonin be used to diagnose Gram-negative bloodstream infection? Evidence based on a meta-analysis [J]. *Eur Rev Med Pharmacol Sci*, 2017, 21 (14): 3253-3261
- [28] Machin M, Amaral AF, Wielscher M, et al. Systematic review of lung function and COPD with peripheral blood DNA methylation in population based studies[J]. *BMC Pulm Med*, 2017, 17(1): 54

- nary Artery Disease[J]. PLoS One, 2015, 10(5): e0126767
- [14] Dogan S, Celikbilek M, Yilmaz YK, et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2015, 27(3): 298-304
- [15] DiNicolantonio JJ, Lucan SC, O'Keefe JH. The Evidence for Saturated Fat and for Sugar Related to Coronary Heart Disease[J]. Prog Cardiovasc Dis, 2016, 58(5): 464-472
- [16] 海日,赵军,李昊真,等.胆固醇对冠状动脉粥样硬化性心脏病的影响[J].内蒙古医科大学学报, 2016, 38(3): 273-276
Hai Ri, Zhao Jun, Li Hao-zhen, et al. Effect of Cholesterol on Coronary Atherosclerotic Heart Disease [J]. Journal of Inner Mongolia Medical University, 2016, 38(3): 273-276
- [17] Luni FK, Riaz H, Khan AR, et al. Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis [J]. Catheter Cardiovasc Interv, 2017, 89(7): 1168-1175
- [18] Würtz M. Aspirin in coronary artery disease: an appraisal of functions and limitations[J]. Dan Med J, 2015, 62(4): B5011
- [19] Cortellini G, Romano A, Santucci A, et al. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity[J]. Allergy, 2017, 72(3): 498-506
- [20] Luo J, Song W, Yang G, et al. Compound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews[J]. Am J Chin Med, 2015, 43(1): 25-43
- [21] Yin Q, Lu H, Bai Y, et al. A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via aNOX2/ROS/p38 pathway[J]. Br J Pharmacol, 2015, 172(23): 5573-5585
- [22] 李婷,焦文君,秦海凤,等.氯吡格雷联合复方丹参滴丸治疗老年冠心病的疗效及机制探讨 [J]. 中国医院药学杂志, 2014, 34(17): 1504-1507
Li Ting, Jiao Wen-jun, Qin Hai-feng, et al. Effect of clopidogrel combined with compound Danshen drop pill in the treatment of elderly patients with coronary heart disease and analysis of its mechanism of actions [J]. Chinese Journal of Hospital Pharmacy, 2014, 34 (17): 1504-1507
- [23] 张敏,张科林.复方丹参滴丸联合曲美他嗪对冠心病合并左心功能不全患者血液流变学影响及疗效观察[J].陕西中医, 2016, 37(10): 1327-1329
Zhang Min, Zhang Ke-lin. Study on effect of CSDP combined with trimetazidine on hemorheology and clinical efficacy in patients with
- coronary artery disease (CAD) with left ventricular dysfunction [J]. Shaanxi Journal of Traditional Chinese Medicine, 2016, 37 (10): 1327-1329
- [24] 王丽美,许军芳,陈文静,等.复方丹参滴丸联合阿托伐他汀治疗冠心病并高脂血症的疗效分析 [J]. 中国临床保健杂志, 2015, 18(5): 489-492
Wang Li-mei, Xu Jun-fang, Chen Wen-jing, et al. Efficacy of Fufang Danshen dripping pills combined with atorvastatin on coronary heart disease with hyper-lipidemia and its influence on hemorheology [J]. Chinese Journal of Clinical Healthcare, 2015, 18(5): 489-492
- [25] 邓炜,王丽,郑焕君,等.多排螺旋CT研究复方丹参滴丸对人体冠状动脉的扩张作用[J].海南医学, 2016, 27(14): 2313-2315
Deng Wei, Wang Li, Zheng Huan-jun, et al. Expansion effect of compound danshen dripping pill on human coronary artery by Multislice CT[J]. Hainan Medical Journal, 2016, 27(14): 2313-2315
- [26] 吕伟.复方丹参滴丸对冠心病合并糖尿病的疗效[J].中国医药导刊, 2014, 16(1): 105-106
Lv Wei. The Curative Effect of Compound Danshen Dripping Pills on Coronary Heart Complicated with Diabetes Mellitus[J]. Chinese Journal of Medical Guide, 2014, 16(1): 105-106
- [27] Li J, Song M, Jian Z, et al. Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence [J]. J Atheroscler Thromb, 2014, 21(3): 239-247
- [28] Chadha DS, Sumana B, Karthikeyan G, et al. Prevalence of aspirin resistance in Asian - Indian patients with stablecoronary artery disease[J]. Catheter Cardiovasc Interv, 2016, 88(4): E126-E131
- [29] 梁鹍,董守仁,彭欢,等.复方丹参滴丸联合阿司匹林治疗冠心病的临床观察[J].中国药房, 2016, 27(32): 4555-4557, 4558
Liang Kun, Dong Shou-ren, Peng Huan, et al. Clinical Observation of Compound Danshen Dropping Pill Combined with Aspirin in the Treatment of Coronary Heart Disease [J]. China Pharmacy, 2016, 27 (32): 4555-4557, 4558
- [30] 吕玉红,崔国旺,王茜,等.复方丹参滴丸协同阿司匹林对冠心病患者的临床效果及血小板聚集功能的影响[J].世界中西医结合杂志, 2016, 11(8): 1137-1139
Lv Yu-hong, Cui Guo-wang, Wang Qian, et al. Clinical Effects on Coronary Heart Disease and the Impacts on Platelet Aggregation in the Treatment with Compound Danshen Dripping Pills and Aspirin [J]. World Journal of Integrated Traditional and Western Medicine, 2016, 11(8): 1137-1139

(上接第 2969 页)

- [29] 蔡岩,王大伟,郑伟,等.慢性阻塞性肺疾病急性加重期患者的血清链球菌、C 反应蛋白水平及其与肺功能的相关性 [J]. 广西医学, 2015, 37(11): 1620-1623
Cai Yan, Wang Da-wei, Zheng Wei, et al. Serum levels of desmosine
- and C-reactive protein and their correlation with lung function in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Guangxi Medical Journal, 2015, 37(11): 1620-1623
- [30] Sterk PJ. Chronic diseases like asthma and COPD: do they truly exist? [J]. Eur Respir J, 2016, 47(2): 359-361